Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Thursday, April 13, 2023
Saline County doctor in military insurance fraud case gets 8 1/2 years, fined $4.6M
How FDA's latest compounding guidance affects ...
Bulk Drug Substance (BDS) | Species | Nomination |
---|---|---|
Acepromazine maleate | dog, cat, horse | FDA‑2018‑N‑4626‑0114 |
Acetyl‑D‑glucosamine | dog, horse | FDA‑2018‑N‑4626‑0104 |
Actinomycin D | dog, cat | FDA‑2018‑N‑4626‑0106 |
Tuesday, April 11, 2023
FDA Approves First Generic Flumethasone for Certain Anti-inflammatory Responsive Diseases in Cats, Dogs and Horses
Today the U.S. Food and Drug Administration approved Bimasone Injectable Solution, the first generic flumethasone, for certain diseases that cause inflammation in horses, dogs, and cats. Bimasone is recommended for the various rheumatic, allergic, dermatologic and other disease states that are known to be responsive to anti-inflammatory drugs (i.e., corticoids) in these species.
Bimasone is a corticosteroid drug. It contains the same active ingredient (flumethasone) in the same concentration and dosage form as the approved brand name drug product, Flucort, which was first approved for use in horses, dogs, and cats on October 21, 1965.